Caribou Biosciences Announces 2026 Annual Meeting Results and Director Elections

On June 17, 2026, Caribou Biosciences, Inc. held its 2026 Annual Meeting of Stockholders to vote on four key proposals. Stockholders successfully elected three Class II directors—Andrew Guggenhime, David Johnson, and Nancy Whiting—to serve until the 2029 annual meeting. Additionally, the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Notably, stockholders did not approve Proposal 3, which sought to amend the Amended and Restated Certificate of Incorporation to provide for the exculpation of officers from certain breaches of fiduciary duty. While Proposal 4, which allowed for the adjournment of the meeting to solicit further votes for Proposal 3, was approved, the company ultimately decided not to adjourn the meeting. The filing details the specific vote counts for each proposal, including votes for, against, withheld, and broker non-votes. No clinical trial updates or financial guidance were provided in this regulatory filing.